BL-1020 is an investigational drug.
There have been 3 clinical trials for BL-1020.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2011.
The most common disease conditions in clinical trials are Schizophrenia, Disease, and Psychotic Disorders. The leading clinical trial sponsors are BioLineRx, Ltd. and [disabled in preview].